Hengrui Medicine:Access China conference highlights
Solid growth to continue with multiple catalysts ahead.
The two key take-aways include 1) Hengrui already filed PD1 application in 4Q17.
We believe the indications are cHL and esophageal cancer, which is earlier thanstreet consensus. This led to stock rally on Tuesday. Additionally the companyexpects approval in 2018; 2) Hengrui expects growth acceleration in 2018. Webelieve this might be a combination of delayed booking of export profit andother unspecified elements. For 2017, Hengrui reiterated 18-20% domestic salesgrowth and 20% exports growth. As for the products breakdown, traditionaloncology/ anesthetics/ contrast agents should reach 10-15%, 20% and over 30%growth respectively in 2017. In addition, lower pricing erosion could be witnessedin FY18 compared with FY17, as secondary negotiations and tenders are largelyconcluded.
Apatinib growth likely to accelerate in 2018; 4Q17 hiccup.
The company indicated that apatinib sales was below expectation in 2017,due to slowdown in 4Q17 stemming from NRDL settlement/ implementationdelays and budget controls. Hengrui remains optimistic on 2018 outlook drivenby reimbursement coverage. Despite the 36% nominal ASP cut of apatinib,management believes the upside could very well outweigh pricing erosion. Assuch, management welcomes negotiations for NRDL/ PRDL rolling inclusionfor key innovative products. In addition, indication expansion studies for livercancer and NSCLC are both progressing to final stages, with approval expectedin 2H18-2019.
Updates on pipeline and other key takeaways.
Four blockbusters are likely to be approved including nab-paclitaxel, 19K,pyrotinib and PD-1. Hengrui commented on bigger addressable market forpyrotinib vs. apatinib, on the back of longer treatment duration, without offeringany color on pricing strategy. On nab-paclitaxel, Hengrui and CSPC are both onpriority review list, with the possibility of obtaining approvals simultaneously. Asfor R&D spending, the ratio is likely to remain at current level, as expense increasewill synchronize with sales growth. On management incentive, the companyimplemented 3 rounds in 2014/16/17, with near-term plan of another round, using3m reserved shares.
- 鐠猴拷婵炶尪濮ら崬鍥槹閻旈攱鎯�(002557)2021妤犵偛鐡ㄦ慨銈夊礆閸℃ḿ鈧粙鏁嶅鑸典粯婵懓鍊藉ù鍡涘汲閺嶃儮鍋撴担铏圭梾闁解偓閵夘灔鏃堝磻閿燂拷 2022-04-12
- 鐠猴拷闂傚洩灏幆鈧悷浣告噹椤︻剙顫楅崒姘倣闁兼祴妲勭槐浼存偋瑜旈悵顔剧箔閿燂拷(603908)闁挎稒淇洪、鎴炵▔濮樺墎鐑﹀璁规嫹2021妤犵偟绻濈粭鐔虹磼閳哄懐褰褏鍋ら弳锟� 2022-04-12
- 鐠猴拷闁荤喓鍋犳慨鍗烆嚗閿燂拷(603893)闁挎稒鐭鍥传娴ｅ湱绠掗柤鐗堟＞IOT 闁瑰灚鎹囬埀顒傚Х閺佹捇骞€娴ｉ绉肩紒顖ゆ嫹 2022-04-12
- 鐠猴拷濞戞搩鍘藉﹢婊勬姜椤栨瑦顐�(688083)闁挎稒鑹炬晶鐘诲疾椤栨氨鐣梻鍐挎嫹 濞存粌鎼幉鎶藉箥閳轰胶鐐� 濞戞搩鍘鹃悡顓㈠嫉閻斿墎鐟圭紓浣叉櫆婢规瑩宕㈤敓锟� 2022-04-12
- 鐠猴拷闁告淇虹缓濂稿棘閻楀牊缍�(605376)闁挎稒宀搁弲顒傚垝婢跺鐛撻柤瀹犲Г鐎垫梻绱掗鐑嗘澔闂傗偓閿燂拷 闁哄倿顣︽鍥传娴ｇ晫妲戝ù鐘活棑鑿欐慨婵勫劜鐢娼婚敓锟� 2022-04-12
- 鐠猴拷閻庣懓绻愭禍鏇犵矓閹寸偛螚(688711)濡絾鐗楅鑲╂啺閸℃瑦纾伴柨娑欑鐎垫梻绱掗鐐茬岛闁告梹绋掗弻濠囨嚄閼恒儳鐖卞Λ鏉挎閻擄拷 濞戞挻姘ㄩ崫妤冣偓鍦仧楠炲洩绠涢锔瑰亾閻斿鏉婚梻鈧敓锟� 2022-04-12
